AtriCure, Inc. (ATRC) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Atricure, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.598 Good afternoon, and welcome to HRECURE's third quarter 2025 earnings 00:00:05.598 -- 00:00:10.624 conference call. This call is being recorded for replay purposes, and 00:00:10.624 -- 00:00:14.870 at this time, all participants are in listen-only mode. 00:00:14.870 -- 00:00:18.715 We will be facilitating a question and answer session 00:00:18.715 -- 00:00:22.419 following prepared remarks from HRECURE's management. 00:00:22.419 -- 00:00:27.085 I would now like to turn the call over to Marissa Beisch from the Gilmartin Group for 00:00:27.085 -- 00:00:30.066 a few introductory comments. 00:00:31.604 -- 00:00:36.750 Thank you. By now, you should have received a copy of the earnings press release. 00:00:36.750 -- 00:00:40.592 If you have not received a copy, please call 513-644-4484 00:00:42.257 -- 00:00:44.559 to have one emailed to you. 00:00:44.559 -- 00:00:48.985 Before we begin today, let me remind you that the company's remarks include forward-looking 00:00:48.985 -- 00:00:50.406 statements. 00:00:50.406 -- 00:00:55.593 Forward-looking statements are subject to numerous risks and uncertainties, many of which 00:00:55.593 -- 00:01:01.237 are beyond HR's control, including risks and uncertainties described from time to time 00:01:01.237 -- 00:01:03.920 and HRCURES SEC filings. 00:01:03.920 -- 00:01:09.405 These statements include, but are not limited to, financial expectations and guidance, 00:01:09.405 -- 00:01:14.470 expectations regarding the potential market opportunity for HRCURES franchises and growth 00:01:14.470 -- 00:01:19.655 initiatives, future product approvals and clearances, competition, 00:01:19.655 -- 00:01:23.479 reimbursement, and clinical trial outcomes. 00:01:23.479 -- 00:01:27.848 HRCURES results may differ mat...